论文部分内容阅读
目的探讨低分子肝素治疗不稳定型心绞痛(UA)的临床疗效及安全性。方法选择46例UA患者随机分成治疗组和对照组,治疗组在对照组严格内科常规药物治疗基础上使用低分子肝素5 000 U皮下注射,每12 h 1次,连用7 d;观察两组心绞痛发作及心电图变化,1周后评定疗效。结果治疗组显效率56.5%,总有效率91.3%;对照组显效率34.8%,总有效率73.9%。两组显效率及总有效率比较差异有统计学意义。结论低分子肝素可使UA患者临床症状及心电图有明显改善,且使用方便,是一种疗效显著、安全、值得临床推广使用的药物。
Objective To investigate the clinical efficacy and safety of low molecular weight heparin in the treatment of unstable angina pectoris (UA). Methods 46 UA patients were randomly divided into treatment group and control group. The treatment group was injected subcutaneously with low-molecular-weight heparin 5000U on the basis of routine medical treatment in the control group once every 12 hours for 7 days. The angina pectoris Episodes and changes in ECG, 1 week after the assessment of efficacy. Results The effective rate of treatment group was 56.5%, the total effective rate was 91.3%; the effective rate of control group was 34.8%, the total effective rate was 73.9%. The two groups markedly effective and total effective rate difference was statistically significant. Conclusion Low molecular weight heparin can significantly improve the clinical symptoms and ECG of UA patients and is convenient to use. It is a kind of effective and safe drug worthy of clinical application.